Assessing factors associated with discharge from opioid agonist therapy due to incarceration in the United States

References

• Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999-2017. Washington (DC): US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2018. p. 1–8.
   Google Scholar
• Centers for Disease C. Overdose data. 2018. https://www.cdc.gov/drugoverdose/index.html
   Google Scholar
• Substance Abuse Mental Health Services Administration, United States. Medication Assisted Treatment. 2019. https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat
   Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–2066. doi:10.1056/NEJMp1402780.
   PubMed Web of Science ®Google Scholar
• Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017;11:286. doi:10.1097/ADM.0000000000000310.
   PubMed Web of Science ®Google Scholar
• Hagedorn H, Kenny M, Gordon AJ, Ackland PE, Noorbaloochi S, Yu W, Harris AH. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addict Sci Clin Pract. 2018;13:25. doi:10.1186/s13722-018-0127-z.
   PubMed Web of Science ®Google Scholar
• Pecoraro A, Ma M, Woody GE. The science and practice of medication-assisted treatments for opioid dependence. Subst Use Misuse. 2012;47:1026–1040. doi:10.3109/10826084.2012.663292.
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662–668. doi:10.1016/S0140-6736(03)12600-1.
   PubMed Web of Science ®Google Scholar
• Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PloS One. 2012;7:e38335. doi:10.1371/journal.pone.0038335.
   PubMed Web of Science ®Google Scholar
• Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat. 2012;43:451–457. doi:10.1016/j.jsat.2012.03.008.
   PubMed Web of Science ®Google Scholar
• Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65:146–157. doi:10.1176/appi.ps.201300235.
   PubMed Web of Science ®Google Scholar
• Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23:63–75. doi:10.1097/HRP.0000000000000075.
   PubMed Web of Science ®Google Scholar
• Metzger DS, Woody GE, O’Brien CP. Drug treatment as HIV prevention: a research update. JAIDS (1999). 2010;55:S32. doi:10.1097/QAI.0b013e3181f9c10b.
   Google Scholar
• United States Office of the White House; 2019. https://www.whitehouse.gov/opioids/
   Google Scholar
• Alexandris Polomarkakis K. Drug law enforcement revisited: The “war” against the war on drugs. J Drug Issues. 2017;47:396–404. doi:10.1177/0022042617697017.
   Web of Science ®Google Scholar
• Bluthenthal R, Lorvick J, Kral A, Erringer E, Kahn J. Collateral damage in the war on drugs: HIV risk behaviors among injection drug users. Int J Drug Policy. 1999;10:25–38. doi:10.1016/S0955-3959(98)00076-0.
   Google Scholar
• Maher L, Dixon TC. Collateral damage and the criminalisation of drug use. Lancet HIV. 2017;4:e326–e327. doi:10.1016/S2352-3018(17)30071-1.
   PubMed Web of Science ®Google Scholar
• Werb D, Hayashi K, Fairbairn N, Kaplan K, Suwannawong P, Lai C, Kerr T. Drug use patterns among Thai illicit drug injectors amidst increased police presence. Subst Abuse Treat Prev Policy. 2009;4:16. doi:10.1186/1747-597X-4-16.
   PubMed Web of Science ®Google Scholar
• Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018;86:104–110. doi:10.1016/j.addbeh.2018.02.024.
   PubMed Web of Science ®Google Scholar
• Brinkley-Rubinstein L, Cloud DH, Davis C, Zaller N, Delany-Brumsey A, Pope L, Martino S, Bouvier B, Rich J. Addressing excess risk of overdose among recently incarcerated people in the USA: harm reduction interventions in correctional settings. Intl J Prisoner Health. 2017;13:25–31. doi:10.1108/IJPH-08-2016-0039.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53:330–333. doi:10.1080/10826084.2017.1363238.
   PubMed Web of Science ®Google Scholar
• Parsons J. Minimizing harm: Public health and justice system responses to drug use and the opioid crisis. New York (NY): Vera Institute of Justice; 2017.
   Google Scholar
• Mitchell O, Caudy MS. Examining racial disparities in drug arrests. Justice Q. 2015;32:288–313. doi:10.1080/07418825.2012.761721.
   Web of Science ®Google Scholar
• Mitchell O, Caudy MS. Race differences in drug offending and drug distribution arrests. Crime Delinq. 2017;63:91–112. doi:10.1177/0011128714568427.
   Web of Science ®Google Scholar
• Kirwan A, Quinn B, Winter R, Kinner SA, Dietze P, Stoové M. Correlates of property crime in a cohort of recently released prisoners with a history of injecting drug use. Harm Reduct J. 2015;12:23. doi:10.1186/s12954-015-0057-y.
   PubMed Web of Science ®Google Scholar
• Felson RB, Staff J. Committing economic crime for drug money. Crime Delinq. 2017;63:375–390. doi:10.1177/0011128715591696.
   Web of Science ®Google Scholar
• Gordon MS, Kinlock TW, Miller PM. Medication‐assisted treatment research with criminal justice populations: challenges of implementation. Behav Sci Law. 2011;29:829–845. doi:10.1002/bsl.1015.
   PubMed Web of Science ®Google Scholar
• Werb D. Post-war prevention: Emerging frameworks to prevent drug use after the War on Drugs. Int J Drug Policy. 2018;51:160–164. doi:10.1016/j.drugpo.2017.06.012.
   PubMed Web of Science ®Google Scholar
• DeBeck K, Wood E, Zhang R, Tyndall M, Montaner J, Kerr T. Police and public health partnerships: Evidence from the evaluation of Vancouver's supervised injection facility. Subst Abuse Treat Prev Policy. 2008;3:11. doi:10.1186/1747-597X-3-11.
   PubMed Web of Science ®Google Scholar
• Ludwig AS, Peters RH. Medication-assisted treatment for opioid use disorders in correctional settings: An ethics review. Int J Drug Policy. 2014;25:1041–1046. doi:10.1016/j.drugpo.2014.08.015.
   PubMed Web of Science ®Google Scholar
• Belenko S, Hiller M, Hamilton L. Treating substance use disorders in the criminal justice system. Curr Psychiatry Rep. 2013;15:414. doi:10.1007/s11920-013-0414-z.
   PubMed Web of Science ®Google Scholar
• Albizu-García CE, Caraballo JN, Caraballo-Correa G, Hernández-Viver A, Román-Badenas L. Assessing need for medication-assisted treatment for opiate-dependent prison inmates. Subst Abuse. 2012;33:60–69. doi:10.1080/08897077.2011.620462.
   PubMed Web of Science ®Google Scholar
• Beletsky L, LaSalle L, Newman M, Paré J, Tam J, Tochka A. Fatal re-entry: legal and programmatic opportunities to curb opioid overdose among individuals newly released from incarceration. NEULJ. 2015;7:149.
   Google Scholar
• Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, Noska A, Reddy M, Zaller N. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386:350–359. doi:10.1016/S0140-6736(14)62338-2.
   PubMed Web of Science ®Google Scholar
• Kresina TF, Litwin A, Marion I, Lubran R, Clark HW. United States government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. J Drug Policy Anal. 2009;2:1–23. doi:10.2202/1941-2851.1007.
   Google Scholar
• Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, Marlowe D, Rosenblum A. Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44:473–480. doi:10.1016/j.jsat.2012.10.004.
   PubMed Web of Science ®Google Scholar
• Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder-and its treatment. JAMA. 2014;311:1393–1394. doi:10.1001/jama.2014.2147.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98:673–684. doi:10.1046/j.1360-0443.2003.00354.x.
   PubMed Web of Science ®Google Scholar
• Sahker E, Toussaint MN, Ramirez M, Ali SR, Arndt S. Evaluating racial disparity in referral source and successful completion of substance abuse treatment. Addict Behav. 2015;48:25–29. doi:10.1016/j.addbeh.2015.04.006.
   PubMed Web of Science ®Google Scholar
• Guerrero EG, Marsh JC, Duan L, Oh C, Perron B, Lee B. Disparities in completion of substance abuse treatment between and within racial and ethnic groups. Health Serv Res. 2013;48:1450–1467. doi:10.1111/1475-6773.12031.
   PubMed Web of Science ®Google Scholar
• Mennis J, Stahler GJ. Racial and ethnic disparities in outpatient substance use disorder treatment episode completion for different substances. J Subst Abuse Treat. 2016;63:25–33. doi:10.1016/j.jsat.2015.12.007.
   PubMed Web of Science ®Google Scholar
• Arndt S, Acion L, White K. How the states stack up: Disparities in substance abuse outpatient treatment completion rates for minorities. Drug Alcohol Depend. 2013;132:547–554. doi:10.1016/j.drugalcdep.2013.03.015.
   PubMed Web of Science ®Google Scholar
• Mutter R, Ali MM, Smith K, Strashny A. Factors associated with substance use treatment completion in residential facilities. Drug Alcohol Depend. 2015;154:291–295. doi:10.1016/j.drugalcdep.2015.07.004.
   PubMed Web of Science ®Google Scholar
• Sahker E, McCabe JE, Arndt S. Differences in successful treatment completion among pregnant and non-pregnant American women. Arch Womens Ment Health. 2016;19:79–86. doi:10.1007/s00737-015-0520-5.
   PubMed Web of Science ®Google Scholar
• Hser Y-I, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi‐site trial. Addiction. 2014;109:79–87. doi:10.1111/add.12333.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35:22–35. doi:10.1080/10550887.2016.1100960.
   PubMed Web of Science ®Google Scholar
• McGovern MP, Xie H, Segal SR, Siembab L, Drake RE. Addiction treatment services and co-occurring disorders: Prevalence estimates, treatment practices, and barriers. J Subst Abuse Treat. 2006;31:267–275. doi:10.1016/j.jsat.2006.05.003.
   PubMed Web of Science ®Google Scholar
• Torrens M, Rossi PC, Martinez-Riera R, Martinez-Sanvisens D, Bulbena A. Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? Subst Use Misuse. 2012;47:1005–1014. doi:10.3109/10826084.2012.663296.
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Feder KA, Saloner B, Crum RM, Kealhofer M, Mojtabai R. The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a US national sample. Drug Alcohol Depend. 2017;175:157–163. doi:10.1016/j.drugalcdep.2017.02.006.
   PubMed Web of Science ®Google Scholar
• Banta‐Green CJ, Maynard C, Koepsell TD, Wells EA, Donovan DM. Retention in methadone maintenance drug treatment for prescription‐type opioid primary users compared to heroin users. Addiction. 2009;104:775–783.
   PubMed Web of Science ®Google Scholar
• Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. 2008;34:123–138. doi:10.1016/j.jsat.2007.01.011.
   PubMed Web of Science ®Google Scholar
• Taxman FS, Henderson CE, Belenko S. Organizational context, systems change, and adopting treatment delivery systems in the criminal justice system. J Subst Abuse Treat. 2009;103:S1–S6.
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS). Discharges, 2015. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2018.
   Google Scholar
• Rabe-Hesketh S, Everitt B. Handbook of statistical analyses using Stata. London UK: Chapman and Hall/CRC; 2010.
   Google Scholar
• Hilbe JM. Logistic regression models. London UK: Chapman and hall/CRC; 2009.
   Google Scholar
• Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. College Park Texas, USA: STATA press; 2008.
   Google Scholar
• Fletcher BW, Lehman WE, Wexler HK, Melnick G, Taxman FS, Young DW. Measuring collaboration and integration activities in criminal justice and substance abuse treatment agencies. Drug Alcohol Depend. 2009;103:S54–S64. doi:10.1016/j.drugalcdep.2009.01.001.
   PubMed Web of Science ®Google Scholar
• Taxman FS, Perdoni ML, Harrison LD. Drug treatment services for adult offenders: The state of the state. J Subst Abuse Treat. 2007;32:239–254. doi:10.1016/j.jsat.2006.12.019.
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Wilson D, Knudsen HK, Ducharme LJ, Welsh WN, Frisman L, Knight K, Lin H-J, James A, Albizu-Garcia CE, et al. Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015;50:50–58. doi:10.1016/j.jsat.2014.10.001.
   PubMed Web of Science ®Google Scholar
• Mohlman MK, Tanzman B, Finison K, Pinette M, Jones C. Impact of medication-assisted treatment for opioid addiction on Medicaid expenditures and health services utilization rates in Vermont. J Subst Abuse Treat. 2016;67:9–14. doi:10.1016/j.jsat.2016.05.002.
   PubMed Web of Science ®Google Scholar
• Rawson R, Cousins SJ, McCann M, Pearce R, Van Donsel A. Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system. J Subst Abuse Treat. 2019;97:84–90. doi:10.1016/j.jsat.2018.11.003.
   PubMed Web of Science ®Google Scholar
• LaBelle CT, Han SC, Bergeron A, Samet JH. Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers. J Subst Abuse Treat. 2016;60:6–13. doi:10.1016/j.jsat.2015.06.010.
   PubMed Web of Science ®Google Scholar
• Alegria M, Carson NJ, Goncalves M, Keefe K. Disparities in treatment for substance use disorders and co-occurring disorders for ethnic/racial minority youth. J Am Acad Child Adolesc Psychiatry. 2011;50:22–31.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Cao D, Guerrero E, Shin HC. Need-service matching in substance abuse treatment: Racial/ethnic differences. Eval Program Plann. 2009;32:43–51.
   PubMed Web of Science ®Google Scholar
• Ojeda VD, Bergstresser SM. Gender, race-ethnicity, and psychosocial barriers to mental health care: An examination of perceptions and attitudes among adults reporting unmet need. J Health Soc Behav. 2008;49:317–334.
   PubMed Web of Science ®Google Scholar
• Mulvaney-Day N, DeAngelo D, Chen CN, Cook BL, Alegría M. Unmet need for treatment for substance use disorders across race and ethnicity. Drug and Alcohol Depend. 2012;125:S44–S50.
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179–187.
   PubMed Web of Science ®Google Scholar
• Jhanjee S. Evidence based psychosocial interventions in substance use. Indian J Psychol Med. 2014;36:112.
   PubMedGoogle Scholar
• Mueser KT, Drake RE, Sigmon SC, Brunette MF. Psychosocial interventions for adults with severe mental illnesses and co-occurring substance use disorders: a review of specific interventions. J Dual Diagn. 2005;1:57–82.
   Google Scholar